Denise Myshko

Articles

Oncology Influencers Explain Do’s and Don’t’s of Social Media

January 12th 2021

Oncologists discuss the use of social media in oncology.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 6th 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

Oncolytics Biotech Launches Trial of Pelareorep/Atezolizumab Combo in Difficult-to-Treat GI Cancers

December 30th 2020

December 30, 2020 - The phase 1/2 GOBLET trial will investigate the use of pelareorep in combination with atezolizumab in patients with metastatic colorectal and advanced or metastatic pancreatic and anal cancers.

BluePrint Subtyping Could be a Predictor of Pertuzumab Benefit in Early Breast Cancer

December 10th 2020

December 10, 2020 - Patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay, showed a trend for greater benefit with adjuvant pertuzumab therapy, according to an exploratory analysis of the data from the APHINITY trial.

Venetoclax/Rituximab Combo Demonstrates Sustained Benefit for Retreated Patients with CLL

December 8th 2020

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

Oral Azacitidine Prolongs Survival in Patients with AML Following Induction, Consolidation Therapy

December 5th 2020

December 5, 2020 - Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.

Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial

November 23rd 2020

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC

November 11th 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

Radiation Oncology Leaders Bristle Over New Medicare Payment Model

November 10th 2020

Practices and cancer centers in randomly selected zip codes will be required to participate in the new radiation oncology Model, which is expected to cover approximately 30% of eligible Medicare fee-for-service care episodes.

Hussain Discusses Progress of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer

November 5th 2020

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.